News & Press Releases

Company announcements and milestones

Company Announcements

2019: Bausch Health Acquisition

Bausch Health completes acquisition of Synergy Pharmaceuticals assets, ensuring continued innovation.

2018: IBS-C Approval

Trulance receives FDA approval for irritable bowel syndrome with constipation.

2017: CIC Approval

Trulance approved by FDA for chronic idiopathic constipation treatment.

Clinical Milestones

Multiple Phase 3 trials demonstrate efficacy and safety of plecanatide.

Important Safety Information — TRULANCE® (plecanatide)

Indication

TRULANCE is indicated for the treatment of adults with chronic idiopathic constipation (CIC) and adults with irritable bowel syndrome with constipation (IBS-C).

Contraindications

TRULANCE is contraindicated in patients less than 6 years of age due to the risk of serious dehydration. Do not use in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings & Precautions

Diarrhea is the most common adverse reaction. If severe diarrhea occurs, suspend dosing and contact a healthcare provider. Safety and efficacy have not been established in patients under 18 years of age; avoid use in pediatric patients.

Additional Information

Use TRULANCE only as prescribed. Discuss all medical conditions, medications, and pregnancy or breastfeeding considerations with a healthcare professional. See product pages for complete details.

View full product overview →